Implementing an Innovative Lipid Management Technique Using siRNA LDL-C Lowering Therapy: Lessons Learned in an NHS

Carl Deaney1, Meredith Donaldson1, Agne Meskauskiene1

  • 1Marsh Medical Practice, Louth, Lincolnshire, UK.

Insights

This UK general practice implemented a new siRNA therapy for lipid management to prevent cardiovascular events. The approach successfully identified at-risk patients and integrated the treatment into primary care, demonstrating achievable enhanced lipid management.

Area of Science:

  • Cardiovascular Disease Research
  • Pharmacology
  • Public Health Initiatives

Background:

  • The UK Government launched a population health agreement to combat cardiovascular disease (CVD).
  • The initiative aims to prevent 150,000 strokes, heart attacks, and dementia cases over 10 years.
  • Inclisiran, a novel siRNA therapy for lowering LDL cholesterol, is central to this strategy.

Purpose of the Study:

  • To share real-world observations of Inclisiran implementation in UK primary care.
  • To assess the potential service benefits of this innovative lipid-lowering therapy.
  • To address patient identification strategies for atherosclerotic cardiovascular disease (ASCVD) risk.

Main Methods:

  • A multi-disciplinary team (MDT) education program utilized existing resources from AHSN and NICE.
  • Automated software searches and manual case-finding identified at-risk patients.
  • Multi-channel patient invitations, informed consent, and automated recall systems were employed for treatment and follow-up.

Main Results:

  • Enhanced lipid management is achievable within primary care, aligning with national guidelines.
  • The implemented methodology and training facilitated rapid identification of eligible patients.
  • A holistic, multi-disciplinary approach minimized service burden on general practitioners (GPs).

Conclusions:

  • Integrated care services can effectively deliver advanced lipid management programs.
  • Leveraging external educational resources supports primary care MDT upskilling and reduces training burdens.
  • The initiative demonstrates a successful model for proactive CVD prevention through enhanced lipid management.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
717
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.6K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K